Teva Pharmaceutical Industries Limited
Stock Forecast, Prediction & Price Target
Teva Pharmaceutical Industries Limited (TEVA) stock Price Target by analysts
$25.75
Potential upside: 47.14%
Teva Pharmaceutical Industries Limited price prediction
What is Teva Pharmaceutical Industries Limited stock analysts` prediction?
Teva Pharmaceutical Industries Limited stock forecast: Based on 3 Wall Street analysts` predicted price targets for Teva Pharmaceutical Industries Limited in the last 3 months, the avarage price target is $25.75, with a high forecast of $NaN. The average price target represents a 47.14% change from the last price of $17.5.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Teva Pharmaceutical Industries Limited stock Price Target by analysts
Full breakdown of analysts given Teva Pharmaceutical Industries Limited price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Ashwani Verma UBS | 25% 1/4 | 9 months ago | $28 60% upside | $21.2 | TheFly | Previous targets (3) |
Balaji Prasad Barclays | 16.67% 1/6 | 9 months ago | $28 60% upside | $21.2 | TheFly | Previous targets (5) |
Balaji Prasad Barclays | 16.67% 1/6 | 11 months ago | $25 42.85% upside | $18.38 | StreetInsider | Previous targets (5) |
Jason Gerberry Bank of America Securities | 0% 0/1 | 12 months ago | $22 25.71% upside | $17.75 | StreetInsider | Previous targets (0) |
Ashwani Verma UBS | 25% 1/4 | about 1 year ago | $26 48.57% upside | $18.43 | StreetInsider | Previous targets (3) |
David Amsellem Piper Sandler | 0% 0/3 | about 1 year ago | $23 31.42% upside | $18.62 | StreetInsider | Previous targets (2) |
Balaji Prasad Barclays | 16.67% 1/6 | about 1 year ago | $22 25.71% upside | $17.43 | TheFly | Previous targets (5) |
Ashwani Verma UBS | 25% 1/4 | about 1 year ago | $24 37.14% upside | $15.81 | TheFly | Previous targets (3) |
Jasper Hellweg Argus Research | 0% 0/1 | about 1 year ago | $20 14.28% upside | $15.81 | TheFly | Previous targets (0) |
Balaji Prasad Barclays | 16.67% 1/6 | over 1 year ago | $21 20% upside | $16.63 | TheFly | Previous targets (5) |
Balaji Prasad Barclays | 16.67% 1/6 | over 1 year ago | $20 14.28% upside | $16.76 | StreetInsider | Previous targets (5) |
David Amsellem Piper Sandler | 0% 0/3 | over 1 year ago | $20 14.28% upside | $16.9 | StreetInsider | Previous targets (2) |
David Amsellem Piper Sandler | 0% 0/3 | over 1 year ago | $19 8.57% upside | $12.01 | StreetInsider | Previous targets (2) |
Unknown J.P. Morgan | N/A | almost 3 years ago | $10 -42.85% downside | $9.48 | Benzinga | N/A |
Ashwani Verma UBS | 25% 1/4 | over 3 years ago | $10 -42.85% downside | $7.89 | TheFly | Previous targets (3) |
Balaji Prasad Barclays | 16.67% 1/6 | over 3 years ago | $13 -25.71% downside | $9.79 | TipRanks Contributor | Previous targets (5) |
Teva Pharmaceutical Industries Limited Financial Estimates
Teva Pharmaceutical Industries Limited Revenue Estimates
Teva Pharmaceutical Industries Limited EBITDA Estimates
Teva Pharmaceutical Industries Limited Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | |
Revenue
% change YoY
| $15.87B N/A | $14.92B -6.00% | $15.84B 6.17% | Avg: $16.62B Low: $16.28B High: $17.06B avg. 4.91% | Avg: $17.04B Low: $16.79B High: $17.34B avg. 2.54% | Avg: $16.49B Low: $16.25B High: $16.78B avg. -3.22% | |
Net Income
% change YoY
| $417M N/A | $-2.35B -664.26% | $-559M 76.24% | Avg: $1.37B Low: $905.53M High: $2.48B avg. 346.04% | Avg: $1.61B Low: $1.08B High: $2.84B avg. 17.08% | Avg: $3.57B Low: $3.50B High: $3.65B avg. 122.00% | |
EBITDA
% change YoY
| $4.52B N/A | $4.10B -9.34% | $1.57B -61.75% | Avg: $4.31B Low: $4.22B High: $4.42B avg. 174.57% | Avg: $4.42B Low: $4.35B High: $4.49B avg. 2.54% | Avg: $4.27B Low: $4.21B High: $4.35B avg. -3.22% | |
EPS
% change YoY
| $0.38 N/A | -$2.12 -657.89% | -$0.5 76.41% | Avg: $1.4 Low: $0.81 High: $2.22 avg. 379.76% | Avg: $1.74 Low: $0.97 High: $2.55 avg. 24.72% | Avg: $3.2 Low: $3.13 High: $3.27 avg. 83.13% | |
Operating Expenses
% change YoY
| $4.49B N/A | $4.28B -4.71% | $4.45B 3.92% | Avg: $3.72B Low: $3.64B High: $3.82B avg. -16.37% | Avg: $3.81B Low: $3.76B High: $3.88B avg. 2.54% | Avg: $3.69B Low: $3.63B High: $3.75B avg. -3.22% | |
FAQ
What is Teva Pharmaceutical Industries Limited stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 161.71% in 2025-2027.
We have gathered data from 7 analysts. Their low estimate is 905.53M, average is 1.37B and high is 2.48B.
What is Teva Pharmaceutical Industries Limited stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 1.41% in 2025-2027.
We have gathered data from 8 analysts. Their low revenue estimate is $16.28B, average is $16.62B and high is $17.06B.
What is Teva Pharmaceutical Industries Limited stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 162.53% in 2025-2027.
We have gathered data from 7 analysts. Their low earnings per share estimate is $0.81, average is $1.4 and high is $2.22.
What is the best performing analyst?
In the last twelve months 3 analysts have been covering Teva Pharmaceutical Industries Limited stock. The most successful analyst is Ashwani Verma whose win rate is 25%. He has correctly predicted 1/4 price targets.